Tempus reported strong second-quarter performance driven by continued growth in its oncology testing business and lifted full-year 2026 revenue guidance. The company said oncology testing revenue grew 31% year over year, supporting total Q2 revenue of $382.5 million and raising expectations for 2026. Management pointed to FDA clearances/approvals for its xT CDx platform and an ongoing review process for its liquid biopsy xF test as key drivers of commercial momentum. Tempus also tied the outlook to the planned acquisition of Personalis, which it expects will expand its minimal residual disease (MRD) capabilities. Tempus’ strategy centers on adoption of molecular tests through reimbursement and coverage decisions, with MRD positioned for continued utilization growth across multiple hematologic indications.